I agree that this site is using cookies. You can find further informations
here
.
X
Login
My folder (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
Show Desktop-Version
Toggle navigation
Burrows, J. F.
962
results:
Articles (Online) X
Search for persons
X
Languages
english (927)
german (2)
Sorted by: Relevance
Sorted by: Year
?
1
Evaluation of variable new antigen receptors (vNARs) as a n..:
Smyth, P.
;
Ferguson, L.
;
Burrows, J. F.
...
Frontiers in Pharmacology. 14 (2023) - p. , 2023
Link:
https://doi.org/10.3389/..
?
2
Octreotide for Gastrointestinal Bleeding in End-Stage Heart..:
Tardo, D.
;
Nanayakkara, P.
;
Kaur, M.
...
Heart, Lung and Circulation. 32 (2023) - p. S168 , 2023
Link:
https://doi.org/10.1016/..
?
3
Combined Plasmapheresis and Complement Inhibition in a High..:
Tardo, D.
;
Carlos, L.
;
Burrows, F.
...
Heart, Lung and Circulation. 32 (2023) - p. S147-S148 , 2023
Link:
https://doi.org/10.1016/..
?
4
Intensive Tacrolimus Level Monitoring After Itraconazole Pr..:
Song, N.
;
Kearney, K.
;
Phan, J.
...
Heart, Lung and Circulation. 32 (2023) - p. S164 , 2023
Link:
https://doi.org/10.1016/..
?
5
HNSCCs overexpressing wild-type HRAS are sensitive to combi..:
Soifer, H.
;
Mishra, V.
;
Malik, S.
...
European Journal of Cancer. 174 (2022) - p. S58 , 2022
Link:
https://doi.org/10.1016/..
?
6
Antitumor Activity of Tipifarnib and PI3K Pathway Inhibitor..:
Smith, A.
;
Chan, S.
;
McCloskey, A.
...
International Journal of Radiation Oncology*Biology*Physics. 112 (2022) 5 - p. e48 , 2022
Link:
https://doi.org/10.1016/..
?
7
Antitumor activity of tipifarnib and PI3K pathway inhibitor..:
Burrows, F.
;
Shivani, M.
;
Wang, Z.
...
European Journal of Cancer. 138 (2020) - p. S43-S44 , 2020
Link:
https://doi.org/10.1016/..
?
8
TIPIFARNIB IN RELAPSED OR REFRACTORY ANGIOIMMUNOBLASTIC T‐C..:
Witzig, T.
;
Sokol, L.
;
Kim, W.
...
Hematological Oncology. 37 (2019) S2 - p. 64-65 , 2019
Link:
https://doi.org/10.1002/..
?
9
Sound and light in ICU during different environmental condi..:
Breeding, J.
;
Buscher, H.
;
Nair, P.
...
Australian Critical Care. 31 (2018) 2 - p. 135 , 2018
Link:
https://doi.org/10.1016/..
?
10
Preliminary Results From a Phase 2 Trial of Tipifarnib in H..:
Ho, A.
;
Chau, N.
;
Garcia, I. Brana
...
International Journal of Radiation Oncology*Biology*Physics. 100 (2018) 5 - p. 1367 , 2018
Link:
https://doi.org/10.1016/..
?
11
Recurrent Cytomegalovirus Infections in Heart Transplant Re..:
Offen, S.
;
Letchford, D.
;
Carlos, L.
...
Heart, Lung and Circulation. 27 (2018) - p. S125 , 2018
Link:
https://doi.org/10.1016/..
?
12
PRELIMINARY RESULTS FROM AN OPEN‐LABEL, PHASE II STUDY OF T..:
Witzig, T.
;
Sokol, L.
;
Jacobsen, E.
...
Hematological Oncology. 35 (2017) S2 - p. 251-252 , 2017
Link:
https://doi.org/10.1002/..
?
13
Systemic inflammation affects reperfusion following transie..:
Burrows, F.
;
Haley, M.J.
;
Scott, E.
...
Experimental Neurology. 277 (2016) - p. 252-260 , 2016
Link:
https://doi.org/10.1016/..
?
14
KO-947, a potent and selective ERK inhibitor with slow diss..:
Kessler, L.
;
Chen, J.
;
Guo, X.
...
European Journal of Cancer. 69 (2016) - p. S126 , 2016
Link:
https://doi.org/10.1016/..
?
15
Phase 1 clinical trial of marizomib (MRZ, NPI-0052) in pati..:
Harrison, S.J.
;
Catley, L.
;
Price, T.
...
Clinical Lymphoma Myeloma and Leukemia. 15 (2015) - p. e269 , 2015
Link:
https://doi.org/10.1016/..
1-15